Navigation Links
DURECT Provides an Update to the Memryte Program Under Development,by Voyager Pharmaceutical Corp

CUPERTINO, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- DURECT Corporation announced today that Voyager Pharmaceutical has provided its shareholders with an update on its truncated Phase 3 clinical trial for Memryte, an investigational drug for the treatment of Alzheimer's disease. Voyager has informed its shareholders that they have observed positive outcome trends among women, but no positive effect among men. DURECT has not independently verified the analysis performed or conclusions of Voyager. Based on these results, Voyager has stated that it intends to focus its efforts on developing Memryte for the treatment of Alzheimer's disease in women and on seeking a potential partner for the program.

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company developing pharmaceutical systems based on its proprietary drug delivery platform technologies. The Company currently has a number of late-stage pharmaceutical products in development addressing large markets in pain management, with a number of research programs underway targeting chronic disease and other therapeutic areas. For more information, please visit www.durect.com.

Forward-Looking Statement

The statements in this press release regarding Memryte, its potential performance and attributes, future development plans for Memryte and efforts by Voyager to seek a partner for the program are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Voyager's abilities to attract and reach business terms with a partner for the Memryte program, design, enroll, conduct and complete clinical trials, obtain successful results from such clinical trials, complete the design, developme
'"/>




Page: 1 2

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. XTL Provides Update on Phase I Clinical Trial of XTL-2125
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
8. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
9. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
10. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
11. NeoPharm Provides Update on LE-SN38 Program
Post Your Comments:
(Date:10/22/2014)... , Oct. 22, 2014  Paper Pak ... has developed APLS ® Body Guard Bio, ... the spread of bacteria and virus while protecting ... Body Guard Bio features a rugged, external nylon ... that create a leak-proof inner chamber that contains ...
(Date:10/22/2014)... , October 22, 2014 ... Disposable Gloves Market (Product type, Form, End user, Application ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, ... disposable gloves market. Based on key trends tracked, it ... valued at $7.9 billion by 2020, registering a CAGR ...
(Date:10/22/2014)... 22, 2014  With a vision to ensure ... a Global Pharmaceutical and Biotech manufacturer selects and ... turnkey solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... and aggregated by the Xyntek and Antares solution ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Xyntek and Antares Serialization Solution Protects Pets Too! 2
... , , ... Inc. (Nasdaq: ALXA ) today announced preliminary results from ... in patients with migraine headache. Both AZ-104 dose groups trended ... endpoint, which was defined as pain-relief at the 2-hour time point, ...
... SAN FRANCISCO, Sept. 14 Schering-Plough Corporation (NYSE: ... vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, ... treatment-experienced HIV-infected patients. The results showed that vicriviroc ... increased CD4 cell counts, and was generally well tolerated ...
Cached Medicine Technology:Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache 2Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache 3Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache 4Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache 5Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 2Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 3Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 4Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 5
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... three Ebola cases in Dallas. But, mental health specialists say ... President Barack Obama on Friday appointed an Ebola "czar" ... infected two Dallas nurses who cared for a Liberian man ... Hospital. But the U.S. cases are miniscule in the ...
(Date:10/22/2014)... Los Angeles, California (PRWEB) October 22, 2014 ... Recovery 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; ... the field of Yoga & Recovery. This book is ... and thrive in a life of recovery. , Recovery ... of the 12 Steps; Recovery 2.0 is a guide for ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... (HealthDay News) -- Two sisters in high school have ... Ilina and Medha Krishen use electronic stethoscopes, which electronically ... in breathing patterns or heartbeats. Ilina, a senior ... to find a way to detect early lung damage ... electronic stethoscope, Ilina recorded one breath cycle each from ...
Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotheropeutics, Inc., ... develops novel drug targets that disrupt the advance ... Dr. Anders Boegh Jensen to its Scientific Advisory ... his considerable expertise in biotechnology and molecular biology ...
... to better treatment decisions for respiratory infections, experts say , ... may be able to help doctors determine which patients need ... in the Sept. 9 issue of the Journal of ... test resulted in less antibiotic use. , If the protocol ...
... , NEW BRUNSWICK, N.J., Sept. 8 Johnson ... Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 15th, at ... Surgical Care for Johnson & Johnson, will represent the Company in ... This broadcast will be available to interested investors and ...
... , , LOS ... Dr. Christina Restrepo has achieved diplomate status with the American College ... Restrepo graduated in 2003 from the University of Florida College of ... small animal medicine and surgery at the renowned Animal Medical Center ...
... , RANCHO CORDOVA, Calif., Sept. 8 ThermoGenesis ... that process and store adult stem cells, announced today it will report ... ended June 30, 2009, on Wednesday, September 9, 2009. , , ... Management will host a conference call Wednesday, September 9, 2009 at 2:00 ...
... , , ... Chemistry September 15 at UC Berkeley Campus , , ... hazardous chemicals in the air and water have led scientists to ... troubling health effects are associated with endocrine disrupting chemicals (EDCs) that ...
Cached Medicine News:Health News:GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board 2Health News:Blood Test Narrows Down Need for Antibiotics 2Health News:Blood Test Narrows Down Need for Antibiotics 3Health News:Animal Dermatology Clinic Marina del Rey Announces Dr. Christina Restrepo, DVM Achieves Diplomate Status With the American College of Veterinary Dermatology 2Health News:ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results on September 9 2Health News:ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results on September 9 3Health News:ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results on September 9 4Health News:Inventor of Green Catalysts Offers Solutions for Cleaning Toxins and Pollutants in the Environment 2
Intact PTH EIA Bone and Mineral Metabolism 021-SDX016 Parathyroid Hormone...
EPO EIA Human Cytokines 021-SDX021 Erythropoietin Anemia...
... Immunoscan MPO-ANCA Kit is an enzyme immunoassay ... in human serum of the subclass of ... to be used as an aid in ... family of autoantibodies associated with vasculitic disorders ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
Medicine Products: